Deals and Portfolio Review: Lessons for pharma from a challenging year

Jamie Munro
Global Practice Leader, Portfolio & Licensing
Helen Dowden
Consultant, Portfolio & Licensing
2018 was a year of highs and lows. We saw plenty of big dollar deals and blockbuster launches. But as the year progressed, pharma companies became increasingly selective in their dealmaking, sharpening their focus on premium assets.
The new year begins with uncertainty. The BMS-Celgene megamerger was the largest one yet in what looks like a developing trend. Big pharma ushered in the new year with drug price increases in the US – a clear sign that earnings take precedence over politics. Yet, political and economic forces drive a shifting and unpredictable global landscape. The Clarivate Analytics Deals and Portfolio Review is back to help you prepare.
Our experts will dig into the strategies behind last year’s biggest deals and key portfolio decisions. You’ll hear a breakdown by company, therapeutic area and region. You’ll get insight on the region where life sciences dealmaking is rapidly growing. We’ll also take you on a deeper dive into the oncology drug development landscape: Are the drivers in place for its continued dominance in 2019?